AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
5.08
-0.14 (-2.68%)
At close: Nov 20, 2026, 4:00 PM EST
5.10
+0.02 (0.39%)
After-hours: Nov 20, 2026, 7:30 PM EST
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or 4.55% compared to the previous year. That makes AN2 Therapeutics the 38,151st largest employer in the world and 5,441st in the United States.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,660,952
Market Cap
192.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Cabaletta Bio | 158 |
| AC Immune | 122 |
| MediWound | 121 |
| Arcturus Therapeutics Holdings | 111 |
| Lineage Cell Therapeutics | 77 |
| Alpha Cognition | 71 |
| Pyxis Oncology | 56 |
ANTX News
- 1 day ago - AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference - Business Wire
- 6 days ago - AN2 Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 11 days ago - AN2 Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 12 days ago - AN2 Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 13 days ago - AN2 Therapeutics reports Q3 EPS (17c), consensus (20c) - TheFly
- 13 days ago - AN2 Therapeutics sees cash runway into 2029 - TheFly
- 13 days ago - AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 13 days ago - AN2 Therapeutics Quarterly report: Q3 2026 - Filings